SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., (FibroGen) a biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs, announced that it has filed a registration statement on Form S‐1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock. All shares in the offering will be sold by FibroGen. The number of shares to be offered and the price range for the offering have not yet been determined.
Goldman, Sachs & Co., Citigroup Global Markets Inc., and Leerink Partners LLC will act as joint book-running managers of the offering.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering can be obtained from Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, via telephone at (866) 471-2526 or by email to firstname.lastname@example.org; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone at (800) 831-9146 or by email to email@example.com; or Leerink Partners LLC, Attn: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, via telephone at (800) 808-7525, ext. 6142 or by email to firstname.lastname@example.org.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
FibroGen is a privately-held biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. FibroGen’s FG-3019 fully human monoclonal antibody is in clinical development for treatment of idiopathic pulmonary fibrosis and other proliferative diseases, including pancreatic cancer and liver fibrosis. Roxadustat (FG-4592), FibroGen’s small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, is currently in clinical development for the treatment of anemia in chronic kidney disease patients who are dialysis-dependent, including hemodialysis and peritoneal dialysis, and not dialysis-dependent.